. 2018 May 17;136(7):747–752. doi: 10.1001/jamaophthalmol.2018.1501

Table 1. Use of Adjuvant Therapy According to Pathology Features in Initially Enucleated Patients With Stage I Unilateral Retinoblastoma^a.

Treatment Group	Pathology Features	Adjuvant Therapy
Low risk (n = 84)	Intraretinal invasion only, prelaminar optic nerve, isolated choroid	Not scheduled
High risk (n = 42)	Postlaminar optic nerve, scleral invasion	Regimen 1 at weeks 0, 6, 12, and 18^b
High risk (n = 42)	Postlaminar optic nerve, scleral invasion	Regimen 2 at weeks 3, 9, 15, and 21^c

^{^a}

According to the International Retinoblastoma Staging System.

^{^b}

Four alternating cycles of regimen 1 (cyclophosphamide [65 mg/kg/d] [plus sodium-2-mercaptoethane sulfonate], idarubicin hydrochloride [10 mg/m²/d], and vincristine sulfate [0.05 mg/kg/d]).

^{^c}

Four cycles of regimen 2 (carboplatin [500 mg/m²/d, days 1 and 2] and etoposide [100 mg/m²/d, days 1-3]).

Table 1. Use of Adjuvant Therapy According to Pathology Features in Initially Enucleated Patients With Stage I Unilateral Retinoblastomaa.

Table 1. Use of Adjuvant Therapy According to Pathology Features in Initially Enucleated Patients With Stage I Unilateral Retinoblastoma^a.